Shares of TiGenix – American Depositary Shares (NASDAQ:TIG) have received an average broker rating score of 2.50 (Hold) from the four brokers that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. TiGenix – American Depositary Shares’ rating score has declined by 150% in the last 90 days as a result of various analysts’ ratings changes.
Brokers have set a 1 year consensus price objective of $36.40 for the company, according to Zacks. Zacks has also given TiGenix – American Depositary Shares an industry rank of 185 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of TiGenix – American Depositary Shares from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. BidaskClub upgraded shares of TiGenix – American Depositary Shares from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. BTIG Research lowered shares of TiGenix – American Depositary Shares from a “buy” rating to a “neutral” rating in a report on Tuesday, January 16th. They noted that the move was a valuation call. Finally, Canaccord Genuity lowered shares of TiGenix – American Depositary Shares from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $50.00 to $42.80 in a report on Monday, January 8th.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3297638/analysts-set-36-40-target-price-for-tigenix-american-depositary-shares-nasdaqtig.html.
TiGenix – American Depositary Shares Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.